Company is guiding pre-NDA before end of Q1 2019 and will have more clarity on its confirmatory study design.
Investors should be looking forward to the Q2 2019 top-line results from the full HOPE Study. There are additional 117 patients that will have their data presented.
Commercialization plan is underway and GBT will be first to capture a $3-billion sickle cell disease market.
Compassionate patients won't stop taking the drug, and these patients have been on drug for more than two years.
Global Blood Therapeutics' Drug is Effective - No Doubt
To refresh investors' memory, Global Blood Therapeutics (GBT) released positive data from a Phase 3 clinical trial, HOPE, evaluating voxelotor in patients at least